Call for project proposals, supported by a research grant from Primary Care Diabetes Europe
Deadline for submission of applications: 1st September 2020
- Programme and Research Focus
- Support and Review Process
- Applications process
- Official application form
- Requirements during the review process
- Reporting Requirements and Approval of Funding
Generating research output and encouraging young and up-and-coming researchers is one of the pillars of Primary Care Diabetes Europe (PCDE). The society encourages high quality research into treatment outcomes and evaluations of new treatment options diabetes in primary care. Working through its research arm, the Primary Care Study Group of European Association for the study of Diabetes, PCDE aims to build a European network of primary care researchers, with wide interests on diabetes and to share research findings.
Programme and Research Focus
The Study Group Research focus spans from screening through to diagnosis, management, avoidance and treatment of complications and reversal of diabetes where possible in the primary care setting. The Programme is supported by an educational research grant from Primary Care Diabetes Europe.
To achieve the goals and objectives of this Programme, the SG invites applications by issuing a call for research proposals from all of its members.
Proposals may include but are not limited to:
- Prevention of diabetes
- Appropriate diagnosis of diabetes in primary care
- Early control and avoidance of therapeutic inertia in primary care
- Various treatment options.
- Adherence and persistence
- Treatment of diabetes complications
- Epidemiology of diabetes and its complications.
- New and advance treatment options in diabetes
- Models of diabetes care
This year the theme of the research call also includes identifying factors associated with adverse clinical outcomes (including but not limited to hospitalisation, ITU admission or death) in people with diabetes mellitus and Covid-19 infection and thereafter to rapidly develop and implement clinical guidance aimed at addressing the modifiable risk factors identified in the hope of reducing future adverse outcomes associated with Covid-19 infection in this highly vulnerable population.
Proposals may include but are not limited to:
- Prevention of COVID-19 complications in people with diabetes
- Appropriate interventions for people with COVID 19 and diabetes in primary care
- Impact of good HbA1c and other cardiovascular risk factor control no COVID 19 severity
- The impact of various treatment options on COVID 19 in people with diabetes.
- Adherence, persistence and de-prescribing in people with diabetes during COVID 19 disease.
- Risk of incident diabetes and its complications in COVID19 infections
- Epidemiology of diabetes and COVID 19.
- Models of diabetes care management in the COVID 19 pandemic.
Studies types can be systematic reviews and meta-analysis, service evaluations, quality improvement projects, big data analysis, feasibility or
Support and Review Process
Research will be supported through the award of grants, each of up to Euro 10,000, although a higher grant could be considered for outstanding projects and provided that the financial expenditure is properly documented. Half of the total budget will be paid at the beginning of the project and the second half on completion. The duration of each award may be one year to 18 months, depending upon the needs of the project and as justified in the application. The Study Group will support the delivery of the projects through the use of subcommittees. These subcommittees may recommend an award in a different amount from that requested, but which is considered more appropriate for the proposed studies.
The grant can also be used to support studies forming part of a larger project, on-going or being planned, provided a good justification is provided in application.
Applications for SG grants are invited from study group members, single non-profit institutions or groups of such institutions from Europe. The principal investigator must be employed full-time or part-time at a non-profit institution and the study must be performed at their place of work. Any other co-investigators can be from any other institution or free-lance.
Applications will be subject to scientific review by 2 independent reviewers; a specialised and independent external reviewer and the investigators suggested reviewer. As the epidemic is waning in most countries, it is anticipated that applications will be received, reviewed and approved for funding by October15th 2020.
Prior to any final decision on funding, and in order to offer applicants the opportunity to benefit from the review process, the SG reserves the right to request revision to applications in accordance with the recommendations of the Review Committee.
Applications for research grants may be subjected to pre-review (or triage) procedures. In this event, any application rejected at pre-review will not be subject to a complete scientific review and no feedback report will be provided to the applicant.
The deadline for receipt of research grant applications for funding this year is 1st September 2020.
All budgets are to be prepared in Euro. For countries in which the Euro is not the common currency, the exchange rate (between the Euro and the local currency in the country where the work is to be performed) used for calculating the Euro budget must be mentioned under “Budget and Costings”.
Applications for this grant must be submitted via email to firstname.lastname@example.org
Members of PCDE and study group members are encouraged to email their applications to the secretariat before the deadline.
Official application form
All applications must be prepared on the official application form (see template) in strict accordance with the detailed instructions to be found there. Applications which do not comply with the instructions given in the application system will not be considered for review.
Requirements during the review process
Completed applications will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate and independent scientific committee.
Review criteria are as follows:
- Significance to primary care: Does the study address an important problem in keeping with the goals and focus areas of PCDE?
- Approach: Are the conceptual framework, design, methods and analyses adequately developed, well integrated, and appropriate to the aims of the project?
- Innovation: Does the project employ novel concepts, approaches or methods? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies?
- Investigator: Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers, if any?
- Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support?
- Budget and feasibility: Is the requested budget appropriate for the proposed study? Is the requested duration suitable for completion of the project within twelve to eighteen months?
- Contribution towards a larger research project: Is the work described in the application intended as part of a larger project? If so, is there any overlap? Is there a clear explanation how the new work will contribute towards the overall success of that larger project?
Reporting Requirements and Approval of Funding
All investigators funded by the SG are required to submit a scientific report at the end of the project period if the manuscript has not yet been published at the end of the project. An interim progress reports will also be required. The Final or report or the publications must have been received prior to the release of the final payments.
Investigators must provide the SG with copies of papers accepted for publication and must acknowledge the support of the PCDE in all written material by use of the phrase: “ This study was initiated and completed independently by Primary Care Diabetes Europe (PCDE).
PCDE as a society, has received sponsorship from Novo Nordisk, Eli Lilly, and Roche Diagnostics, but the companies had no input in the study”.
|Announcement||15ST July 2020|
|Application Deadline||1st September 2020|
|Anticipated Award Date||15th October 2020|